scholarly journals The Challenges of Measuring and Valuing Quality of Life in Preschool Children: A Retrospective Review of NICE Appraisals

Children ◽  
2021 ◽  
Vol 8 (9) ◽  
pp. 765
Author(s):  
Alan Lamb ◽  
Alice Murray ◽  
Rosie Lovett

Health technology assessment agencies evaluate interventions across the lifespan. However, there is no consensus about best-practice methods to measure health-related quality of life (HRQoL) in preschool children (<5 years) and data are often scarce. We reviewed methods used to capture the HRQoL of preschool children in past National Institute for Health and Care Excellence (NICE) appraisals to establish whether there is a need for better methods in this area and if so, to identify priority research areas. We identified past NICE appraisals that included preschool children, examining the methods used to generate utility values and whether committees believed these captured HRQoL adequately. Of the 12 appraisals, most used generic HRQoL measures designed for adults. Measures were usually completed by adult patients or clinical experts. Committees frequently commented on limitations in the HRQoL data. While acknowledging that data collection may be challenging, committees would value evidence based on HRQoL data from parents or guardians collected as part of a clinical trial. We identified several research priorities including the psychometric properties of existing measures; the feasibility and validity of valuation studies; and mapping. Progress in these areas will help ensure that the aspects of HRQoL which matter to children and their families are captured in NICE evaluations.

2014 ◽  
Vol 25 (2) ◽  
pp. 117-126 ◽  
Author(s):  
Raquel Gonçalves Vieira-Andrade ◽  
Paulo Antônio Martins-Júnior ◽  
Patrícia Corrêa-Faria ◽  
Leandro Silva Marques ◽  
Saul Martins Paiva ◽  
...  

Author(s):  
Ennapadam S. Krishnamoorthy ◽  
Vivek Misra

Neuropsychiatry as a medical specialty is significantly underrepresented in India, with neurology and psychiatry giving each other a wide berth in many of the country’s regions. This chapter reviews the state of neuropsychiatric services in India and South Asia, before moving on to explore what constitutes a Comprehensive Neuropsychiatry Programme (CNP). This encompasses education and research into neuropsychiatric outcomes, advocacy at a governmental level, and community-engendered activities, all with a view to attaining optimal levels of participation in activities of daily living (ADLs), health-related quality of life (HRQoL), and various social and educational milestones. The model employed by a multidisciplinary team for use in developing nations is then described, along with a case study to demonstrate best practice.


2009 ◽  
Vol 43 (5) ◽  
pp. 813-821 ◽  
Author(s):  
Ripple Talati ◽  
Olivia J Phung ◽  
Jeffrey Mather ◽  
Craig I Coleman

Background Non-ergot dopamine agonists (NEDAs) have become the gold-standard agents for the treatment of restless legs syndrome (RLS). While the efficacy and safety of these drugs have been widely studied, their effect on patients' health-related quality of life (HRQoL) has not been fully elucidated. Objective To better define the usefulness of NEDAs by assessing their impact on HRQoL. Methods We performed a meta-analysis of randomized, double-blind, placebo-controlled trials evaluating the use of NEDAs in patients with RLS. A systematic literature search of MEDLINE, EMBASE, and Cochrane CENTRAL was performed from the earliest possible date through July 2008. Trials were included in the analysis if they evaluated NEDAs for the treatment of RLS and reported HRQoL using any RLS disease-specific HRQoL instrument. HRQoL data were pooled and evaluated using an inverse variance weighting approach as standardized mean differences (SMDs) and 95% confidence interval (CI). For trials reporting HRQoL data obtained using the Johns Hopkins RLS-QoL Questionnaire, adjusted mean difference data were pooled to calculate the weighted mean difference (WMD) and 95% CI. Results Seven trials (N = 1483) met all inclusion criteria. Patients with RLS taking NEDAs had significantly improved overall effect on HRQoL compared with those taking placebo (SMD 0.20; 95% CI 0.10 to 0.30; degree of inconsistency across studies [I2] = 0%). When analyzing trials using the Johns Hopkins RLS-QoL questionnaire, the results also showed improvement with NEDAs compared with placebo (WMD 4.72; 95% CI 2.96 to 6.47; I2 = 0%). Study conclusions were unchanged upon sensitivity analysis. The number of trials for each NEDA was small, limiting the usefulness of between-agent comparisons. Conclusions In patients with RLS, use of NEDAs showed improved HRQoL compared with placebo. Since pooled effect sizes observed in this meta-analysis appear to surpass accepted values for minimally important clinical differences, these improvements may be clinically relevant for the average studied patient. However, future studies evaluating long-term treatment of RLS with NEDAs are necessary, as are head-to-head comparative trials and economic assessments.


Cancers ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 3502
Author(s):  
Marijke B. Coomans ◽  
Marthe C.M. Peeters ◽  
Johan A.F. Koekkoek ◽  
Jan W. Schoones ◽  
Jaap Reijneveld ◽  
...  

Background: Health-related quality of life (HRQoL) has become an increasingly important patient-reported outcome in glioma studies. Ideally, collected HRQoL data should be exploited to the full, with proper analytical methods. This systematic review aimed to provide an overview on how HRQoL data is currently evaluated in glioma studies, focusing on the research objectives and statistical analyses of HRQoL data. Methods: A systematic literature search in the databases PubMed, Embase, Web of Science and Cochrane was conducted up to 5 June 2020. Articles were selected based on predetermined inclusion criteria and information on study design, HRQoL instrument, HRQoL research objective and statistical methods were extracted. Results: A total of 170 articles describing 154 unique studies were eligible, in which 17 different HRQoL instruments were used. HRQoL was the primary outcome in 62% of the included articles, and 51% investigated ≥1 research question with respect to HRQoL, for which various analytical methods were used. In only 42% of the articles analyzing HRQoL results over time, the minimally clinical important difference was reported and interpreted. Eighty-six percent of articles reported HRQoL results at a group level only, and not at the individual patient level. Conclusion: Currently, the assessment and analysis of HRQoL outcomes in glioma studies is highly variable. Opportunities to maximize information obtained with HRQoL data include appropriate and complementary analyses at both the group and individual level, comprehensive reporting of HRQoL results in separate articles or supplementary material, and adherence to existing guidelines about the assessment, analysis and reporting of patient-reported outcomes.


2013 ◽  
Vol 13 (1) ◽  
Author(s):  
Jardena Puder ◽  
Ana Margarida Pinto ◽  
Antoine Bonvin ◽  
Patrick Bodenman ◽  
Simone Munsch ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document